Shares of Amarin Corp. jumped 64.79% after the company announced positive preliminary developments from a Phase III clinical trial for AMRN's omega-3 compound AMR101.
A research note by analysts at Canaccord Genuity stated that AMRN's AMR101 appears to have a superior efficacy and safety profile than Lovaza. Lovaza, product of GlaxoSmithKline (GSK), is the only omega-3 treatment for high triglycerides currently approved by the FDA.
AMRN stock price closed at $5.85 a share, a gain of nearly 65%.
Amarin Corp AMRN stock price quote chart



